ResApp (ASX:RAP) strikes another deal with AstraZeneca; share price soars

Renowned digital health company ResApp Health Limited (ASX:RAP) announced on Friday that it has secured a one-year, non-exclusive licensing agreement with AstraZeneca K.K. to licence its cough counting technology for use in a programme to support asthma patients. 

ResApp is a Company involved in developing smartphone applications for the diagnosis and management of respiratory diseases. 

As per the deal, ResApp’s cough counting technology will be integrated into AstraZeneca’s direct-to-customer asthma management smartphone application to help patients monitor symptoms in the home setting and support them in managing their asthma.

AstraZeneca’s asthma monitoring application is presently under development and is expected to launch in the coming months. 

Meanwhile, the stock was found trading at A$0.067 per share, up 15.517%, with market capitalisation at A$43.97 million at 11:51 AM AEDT. 

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK